MedTrace Logo

Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice

NCT01793142 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3430

Last updated 2018-12-24

Study results available
· View outcomes & findings →

Summary

This survey is conducted for preparing application material for re examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, and assessing the safety and efficacy profiles of VIVIANT in usual practice according to the Re-examination Regulation for New Drugs

Conditions

Interventions

DRUG

Viviant

Viviant (Bazedoxifene) 20mg once daily

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-24
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01793142 on ClinicalTrials.gov